An Open, Pared Trial of Recombinant Hepatitis E Vaccine (Escherichia Coli) Hecolin® in the Chronic Hepatitis B Patients on the Clinical Stability ( Aged 30 Years or Over).
Phase of Trial: Phase IV
Latest Information Update: 06 Dec 2017
At a glance
- Drugs Recombinant hepatitis E vaccine (Hecolin) (Primary)
- Indications Hepatitis E
- Focus Therapeutic Use
- Sponsors Xiamen Innovax Biotech
- 01 Dec 2017 Status changed from active, no longer recruiting to completed.
- 21 Nov 2016 New trial record